| Purpose | (Clinical Focus: This value set serves as a comprehensive reference for medications used in transfeminine hormone replacement therapy (HRT). It combines three key components:
Antiandrogens: medications that suppress testosterone production or block its effects.
Estrogens: hormones crucial for feminization by promoting breast development, regulating menstrual cycles (in some regimens), and influencing other physiological changes.
GnRH agonists: medications that suppress the production of sex hormones (estradiol and testosterone).),(Data Element Scope: This value set provides a standardized approach to capturing the various medications included in transfeminine HRT regimens. It encompasses a broad range of options across different categories to allow for comprehensive documentation of a patient's HRT plan.),(Inclusion Criteria: The value set references three underlying child value sets:
"Transfeminine Regimens, Antiandrogens": captures various antiandrogens like spironolactone with different dosages and formulations (oral tablets, capsules, suspension).
"Transfeminine Regimens, Estrogens": includes a wide range of estradiol medications including injectable forms, transdermal patches, and topical gels with varying dosages and delivery methods.
"Transfeminine Regimens, GnRH Agonists": focuses on leuprolide acetate and goserelin medications used for testosterone suppression, including various injection formulations and implant options.),(Exclusion Criteria: The value set relies on the underlying child value sets for specific details on medications and dosages.
It does not capture information about the specific sequence or combination of medications used in a particular HRT regimen.
It does not include other medications that may be part of transgender healthcare, such as supplements or medications for specific health conditions.) |
FHIR